Lode Debrabandere
Directeur/Membre du Conseil chez Prolexys Pharmaceuticals, Inc.
Profil
Lode Debrabandere is currently a Director at Prolexys Pharmaceuticals, Inc. He previously worked as the President, Chief Executive Officer & Director at Osiris Therapeutics, Inc. from 2014 to 2016.
He was also the President, Chief Executive Officer & Director at Elutia, Inc. and a Vice President-Strategic Marketing at Bristol Myers Squibb Co. Dr. Debrabandere holds an MBA and a doctorate from Katholieke Universiteit Leuven.
Postes actifs de Lode Debrabandere
| Sociétés | Poste | Début |
|---|---|---|
Prolexys Pharmaceuticals, Inc.
 Prolexys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Prolexys Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering small molecule drugs that act at novel therapeutic targets. The Company's therapeutic focus is on cancer and cardiovascular indications. Prolexys scientists have exploited proprietary proteomics-related techniques to rapidly and accurately identify drug candidates that interact with targets of interest. The result of targeted drug discovery work at Prolexys is a pipeline of product candidates with high value in areas of unmet medical need. Lead programs include: a) Solid tumor oncology program with a small molecule clinical candidate with selective anti-tumor activity, b) The colon cancer program with novel small molecule compounds targeting the beta-catenin signaling cascade and c) HSP20 antagonists, identified as protein interaction inhibitors from targets validated in asthma and vasorelaxation. | Directeur/Membre du Conseil | - |
Anciens postes connus de Lode Debrabandere
| Sociétés | Poste | Fin |
|---|---|---|
| ELUTIA INC. | Directeur Général | 04/06/2018 |
| OSIRIS THERAPEUTICS, INC. | Directeur Général | 03/02/2016 |
| BRISTOL-MYERS SQUIBB COMPANY | Sales & Marketing | - |
Formation de Lode Debrabandere
| Katholieke Universiteit Leuven | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| ELUTIA INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Osiris Therapeutics, Inc.
 Osiris Therapeutics, Inc. BiotechnologyHealth Technology Osiris Therapeutics, Inc. engages in the research, development, manufacture, and commercialization of regenerative medicine products. Its biosurgery business focuses on using unique tissue preservation technologies to develop viable human tissue products designed to improve wound closure and surgical outcomes for patients and physicians over standard of care alone. The company was founded by Peter A. Friedli and James S. Burns on December 23, 1992 and is headquartered in Columbia, MD. | Health Technology |
Prolexys Pharmaceuticals, Inc.
Prolexys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Prolexys Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering small molecule drugs that act at novel therapeutic targets. The Company's therapeutic focus is on cancer and cardiovascular indications. Prolexys scientists have exploited proprietary proteomics-related techniques to rapidly and accurately identify drug candidates that interact with targets of interest. The result of targeted drug discovery work at Prolexys is a pipeline of product candidates with high value in areas of unmet medical need. Lead programs include: a) Solid tumor oncology program with a small molecule clinical candidate with selective anti-tumor activity, b) The colon cancer program with novel small molecule compounds targeting the beta-catenin signaling cascade and c) HSP20 antagonists, identified as protein interaction inhibitors from targets validated in asthma and vasorelaxation. | Health Technology |
